Zydus Lifesciences Ltd

Easy Trip Planners Ltd, Dhani Services Ltd, Mahanagar Gas Ltd and Astrazeneca Pharma India Ltd are among the other losers in the BSE's 'A' group today, 16 April 2025.Zydus Lifesciences Ltd crashed 7.65% to Rs 816.55 at 14:47 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 2.23 lakh shares were traded on the counter so far as against the average daily volumes of 74937 shares in the past one month.Easy Trip Planners Ltd tumbled 7.27% to Rs 12.38. The stock was the second biggest loser in 'A' group.On the BSE, 66.17 lakh shares were traded on the counter so far as against the average daily volumes of 42.67 lakh shares in the past one month.Dhani Services Ltd lost 5.04% to Rs 61.24. The stock was the third biggest loser in 'A' group.On the BSE, 3.27 lakh shares were traded on the counter so far as against the average daily volumes of 3.26 lakh shares in the past one month.Mahanagar Gas Ltd shed 4.85% to Rs 1252.1. The stock was the fourth biggest loser in 'A' group.On the BSE, 87191 shares were traded on the counter so far as against the average daily volumes of 12686 shares in the past one month.Astrazeneca Pharma India Ltd corrected 4.53% to Rs 8470. The stock was the fifth biggest loser in 'A' group.On the BSE, 1203 shares were traded on the counter so far as against the average daily volumes of 3644 shares in the past one month.Powered by Capital Market - Live

Zydus Lifesciences  has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Jaythari' (Deflazacort) Tablets, 6 mg, 18 mg, 30 mg, and 36 mg (USRLD: Emflaza ' Tablets, 6 mg, 18 mg, 30 mg, and 36 mg). Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older. Jaythari' (Deflazacort) will be produced at Doppel Farmaceutici S.r.l., Italy facility. The group now has 424 approvals and has so far filed 492* ANDAs since the commencement of the filing process in FY 2003-04. Powered by Capital Market - Live

The product is the generic equivalent of Emflaza tablets, and is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 5 years and older. Jaythari will be manufactured at the group's Doppel Farmaceutici S.r.l. facility in Italy. With this approval, Zydus has now amassed 424 final ANDA (Abbreviated New Drug Application) approvals from the USFDA. The company has filed a total of 492 ANDAs since it began the process in FY 2003-04. Separately, Zydus Lifesciences announced the incorporation of a wholly owned subsidiary in France, named Zydus MedTech (France) SAS, through its Indian arm Zydus MedTech. The move is a strategic step in Zydus's ongoing acquisition of Amplitude Surgical SA, a France-based medical device company. This development follows Zydus's earlier disclosure on 11 March 2025, regarding its agreement to acquire an 85.6% controlling stake in Amplitude Surgical SA via a Block Acquisition, at a price of 6.25 euros per share, totaling a consideration of 256.8 million euros. Upon the successful completion of this block transaction, Zydus intends to launch a mandatory cash tender offer for the remaining shares of Amplitude Surgical at the same price. If conditions are met, the company plans to proceed with a squeeze-out of minority shareholders and subsequently delist the target entity. To facilitate this transaction, Zydus MedTech (France) SAS was incorporated on 10 April 2025, with an authorized share capital of 1,000 euros and a paid-up share capital of 100 euros. As of now, the company has not commenced business operations. The entire shareholding of the new French subsidiary is held by Zydus MedTech, making it a wholly owned step-down subsidiary of Zydus Lifesciences. The investment was made in cash, including a share capital contribution and an issuance premium. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The company reported a 29.62% jump in consolidated net profit of Rs 1,023.5 crore in Q3 FY25 compared with Rs 789.6 crore in Q3 FY24. Revenue from operations increased 17.95% YoY to Rs 5,123.50 crore during the quarter. Powered by Capital Market - Live

Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer. Apalutamide tablets will be produced at Zydus Lifesciences (SEZ), Ahmedabad. Apalutamide tablets had annual sales of $1099.8 million in the United States (IQVIA MAT January 2025). The group now has 420 approvals and has so far filed 483 ANDAs since the commencement of the filing process in FY 2003-04. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The company reported a 29.62% jump in consolidated net profit of Rs 1,023.5 crore in Q3 FY25 compared with Rs 789.6 crore in Q3 FY24. Revenue from operations increased 16.96% YoY to Rs 5,269.1 crore during the quarter. Shares of Zydus Lifesciences rose 0.57% to Rs 908.25 on the BSE.Powered by Capital Market - Live

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Apalutamide Tablets, 60 mg (Erleada' Tablets, 60 mg). Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer. Apalutamide tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad. Apalutamide tablets had annual sales of USD 1099.8 mn in the United States (IQVIA MAT January 2025).Powered by Capital Market - Live

The said inspection was conducted from 10 March to 14 March 2025 and concluded with zero observations from the regulatory body. The official announcement was made on 14 March 2025. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The company reported a 29.62% jump in consolidated net profit of Rs 1,023.5 crore in Q3 FY25 compared with Rs 789.6 crore in Q3 FY24. Revenue from operations increased 16.96% YoY to Rs 5,269.1 crore during the quarter.Powered by Capital Market - Live

Zydus Lifesciences announced that the USFDA conducted a surveillance inspection at the group's API Unit 1, located at Ankleshwar in Gujarat. The inspection was conducted from 10 March to 14 March 2025. The inspection concluded with NIL observations. Powered by Capital Market - Live

The said inspection was conducted from 10 March to 14 March 2025 and concluded with zero observations from the regulatory body. The official announcement was made on 14 March 2025. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The company reported a 29.62% jump in consolidated net profit of Rs 1,023.5 crore in Q3 FY25 compared with Rs 789.6 crore in Q3 FY24. Revenue from operations increased 16.96% YoY to Rs 5,269.1 crore during the quarter. Shares of Zydus Lifesciences fell 0.73% to end at Rs 882.55 on Thursday, 13 March 2025.Powered by Capital Market - Live

Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), announced its investment in Illexcor Therapeutics (Illexcor), a pioneering biopharmaceutical company developing next-generation oral therapies for sickle cell disease (SCD). This investment underscores Zynext Ventures' commitment to supporting disruptive healthcare innovations that address significant unmet medical needs. Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD. Their lead asset, currently in preclinical development, is designed to bind to Hemoglobin S and effectively block polymerization and sickling, offering the potential for disease-modifying clinical benefits. Speaking on the development, Dr. Sharvil Patel, MD of Zydus Lifesciences, said, 'This investment reflects our commitment to patients battling rare and orphan diseases. Recognizing the profound impact of sickle cell disease on patients' lives, we are pleased to support Illexcor in their efforts to develop a novel therapeutic solution addressing this critical unmet medical need.' Powered by Capital Market - Live

Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD. Their lead asset, currently in preclinical development, is designed to bind to Hemoglobin S and effectively block polymerization and sickling, offering the potential for disease-modifying clinical benefits. The company said that Sickle cell disease is a devastating and debilitating genetic condition that affects up to 10 million people worldwide. The disease continues to severely impact quality of life and longevity. Highly efficacious oral drug therapies are urgently needed to manage this condition on a global scale. Dr. Sharvil Patel, MD of Zydus Lifesciences, said, 'This investment reflects our commitment to patients battling rare and orphan diseases. Recognizing the profound impact of sickle cell disease on patients' lives, we are pleased to support Illexcor in their efforts to develop a novel therapeutic solution addressing this critical unmet medical need.' Andrew Fleischman, CEO of Illexcor stated, 'We are excited to partner with Zynext Ventures to advance our lead drug ILX002 into clinical trials later this year. We are hopeful that ILX002 will be a transformative treatment not only for SCD patients in the U.S. but also for millions around the globe. Zynext Ventures and Zydus Lifesciences are in a strategic position to help us achieve these goals.' Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The company reported a 29.62% jump in consolidated net profit of Rs 1,023.5 crore in Q3 FY25 compared with Rs 789.6 crore in Q3 FY24. Revenue from operations increased 16.96% YoY to Rs 5,269.1 crore during the quarter. The counter shed 0.20% to Rs 887.25 on the BSE. Powered by Capital Market - Live